Top Story Today
A Bispecific Antibody Just Beat Keytruda Where It Matters Most
No drug has ever posted a statistically significant overall survival advantage over Keytruda in a head-to-head monotherapy trial. Until now. Akeso and Summit Therapeutics announced that ivonescimab, a bispecific antibody targeting both PD-1 and VEGF, hit the overall survival endpoint in the Phase III HARMONi-2 trial for first-line PD-L1-positive lung cancer. The drug had already nearly doubled progression-free survival (11.14 vs. 5.82 months). The catch: the trial enrolled primarily Chinese patients, and Western subgroup data haven't reached statistical significance yet. Summit's first FDA decision is set for November 2026 in a narrower indication.
Why it matters: Keytruda generates billions a year from lung cancer alone. A validated competitor with a dual mechanism of action could reshape the entire first-line treatment landscape, accelerating pressure on Merck years before its 2028 patent cliff even arrives.
Read more →Clinical Setbacks and Safety Signals
Ultragenyx's Angelman Syndrome Drug Fails Phase 3, Stock Craters 40%+
Apazunersen showed zero benefit over sham treatment in a 129-patient Phase 3 trial for Angelman syndrome, a rare disorder with no approved therapies. The drug missed both its primary cognitive endpoint and key secondary measures. Shares dropped over 40%, and analysts slashed price targets across the board. The failure underscores the brutal attrition rate in CNS drug development, where roughly 85% of late-stage candidates never make it.
Read more →CRISPR Deaths in China Force a Reckoning Over Viral Delivery
Patient deaths from viral-vector-delivered CRISPR therapies in China are forcing the gene-editing field to confront its delivery problem. A boy with Duchenne muscular dystrophy died after severe immune reactions to AAV vectors. The editing tool worked fine; the biological delivery truck triggered fatal inflammatory responses. Regulators in both Beijing and Washington are tightening oversight.
Read more →Deals and Big Pharma Moves
Novartis Pays $160M Upfront in a Deal Worth Up to $5.2B for Chinese Cardiovascular Biotech
Novartis licensed siRNA-based cardiovascular therapies from China's Argo Biopharmaceutical in one of the largest China-to-pharma deals ever. The centerpiece is a Phase 2 drug targeting dangerous blood fats. It's the third collaboration between the two companies and part of Novartis's aggressive cardio shopping spree, which has included billions in acquisitions over the past two years as it prepares for Entresto's eventual generic competition.
Read more →GSK Bets $1.3B on a Two-Headed KRAS-EGFR Cancer Killer With Zero Human Data
GSK is paying HUTCHMED up to $1.3 billion for HMPL-A830, a first-in-class antibody-targeted therapy conjugate that pairs an anti-EGFR antibody with a KRAS inhibitor payload. The drug hasn't been tested in a single human yet; Phase 1 is slated for late 2026. The deal reflects big pharma's conviction that dual-targeting can break the resistance cycle that has plagued single-agent KRAS drugs.
Read more →Teva's Celiac Disease Drug Aces Phase 2, Eyes a Market With Zero Approved Therapies
TEV-408, an anti-IL-15 antibody, cut gluten-induced intestinal damage roughly in half versus placebo in a 50-patient celiac disease trial. There are currently no approved targeted therapies for celiac, a condition affecting about 1% of the global population. With prior competitor Amgen stumbling and Fast Track designation in hand, Teva now holds the best data in the class.
Read more →Regulatory and Pipeline Milestones
After a Dramatic FDA Reversal, uniQure Files for Approval of Huntington's Gene Therapy
The FDA initially rejected uniQure's plan to file based on external-control data, then reversed course months later. Now AMT-130, a one-time gene therapy delivered directly into the brain, has been submitted for approval. In a small trial, high-dose patients showed 75% slowing of disease progression at three years. If approved, it would be the first disease-modifying treatment for Huntington's, ever.
Read more →FDA Tightens the Screws on Clinical Trial Data From China
The FDA is expanding overseas audits and demanding earlier verification of foreign trial sites, with a sharp focus on China-generated data. Companies that built strategies around running trials in China and filing in America now face a rising bar. Analysts estimate roughly 25 China-based oncology applications are already under heightened scrutiny, and the policy shift could force a wave of multi-regional trial redesigns.
Read more →Zero Relapses in Three Years: A Personalized Cancer Vaccine Posts Striking Phase 1 Data
All 16 patients who received Transgene and NEC's personalized cancer vaccine TG4050 remained disease-free at three years, versus three relapses in the control group. The vaccine uses AI to identify each patient's unique tumor mutations, then encodes them into a viral vector that trains the immune system to hunt residual cancer cells. The trial was small, but the signal in notoriously brutal HPV-negative head and neck cancer is hard to ignore.
Read more →ARPA-H Bets $54.5M on Shrinking an Entire mRNA Factory Onto a Lab Bench
A six-company consortium led by Waterfall Scientific received up to $54.5 million to build a continuous-flow, benchtop-sized mRNA manufacturing system. The goal: replace massive batch facilities with compact machines that could produce personalized medicines on demand. If it works, the technology could unlock patient-specific cancer vaccines and rare disease treatments that current manufacturing simply can't support.
Read more →